This article is more than 5 years old. Information may no longer be current.

Vexim reports 34% sales growth in 2015

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Vexim, a medical device company specializing in spine trauma, recently announced a 34% annual sales increase compared with its 2014 sales and its highest ever fourth-quarter sales growth.

In the fourth quarter of 2015, Vexim’s sales reached 4.2 million euros, an increase of 44% from the same period in 2014. These quarterly sales results are the best recorded since the company’s creation, according to a company press release.

Vexim’s sale growth accelerated in the second semester of the year, which the company attributed to its successful market penetration of SpineJack largely through direct sales to hospitals in Europe (89% of sales) and specialized distributors in other territories. Sales growth increased from 24% in the first semester of 2015 to 44% in the second semester, according to the release.

SpineJack has sold more than 27,500 units since its market launch, according to the release. The company continues to be in line with its growth strategy as defined at the time of Vexim’s initial public offering in 2012. Vexim will aim to increase its European market share from an estimated 7% at the end of 2015 to 20% by the end of 2017, according to the release.

Reference: 

www.vexim.com